• Asahi Kasei will consolidate its pharmaceutical operations under the Asahi Kasei Therapeutics brand, creating a single global management structure.
• Integration covers Japan’s Asahi Kasei Therapeutics, U.S.-based Veloxis, Sweden’s Calliditas, Germany’s AiCuris, aligning oversight across geographies.
• Move supports a ¥300 billion pharmaceutical net sales target by FY2030, with investment plans including about ¥40 billion for in-licensing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.